基础医学与临床 ›› 2017, Vol. 37 ›› Issue (6): 884-888.

• 短篇综述 • 上一篇    下一篇

卡培他滨联合化疗双周方案研究进展

马守东1,孙国贵2,张弘纲3   

  1. 1. 唐山市人民医院/肿瘤医院
    2. 河北省唐山市人民医院
    3. 中国医学科学院 肿瘤医院
  • 收稿日期:2016-05-03 修回日期:2016-07-01 出版日期:2017-06-05 发布日期:2017-05-26
  • 通讯作者: 马守东 E-mail:tsmsd@sina.com

Research progress of capecitabine combined chemotherapy with biweekly scheme

  • Received:2016-05-03 Revised:2016-07-01 Online:2017-06-05 Published:2017-05-26
  • Contact: Shoudong Ma E-mail:tsmsd@sina.com

摘要: 卡培他滨作为口服化疗药物,具有安全、有效和使用方便的特点,已经广泛应用于包括食管癌、胃癌、大肠癌、乳腺癌和卵巢癌等多种实体肿瘤的化疗。既往用药主要为3周方案,即每周期化疗口服卡培他滨14d,停药7d。作为对传统化疗方案的改良,卡培他滨双周方案显示出毒副反应降低、患者耐受性好、住院时间短等特点,值得临床应用推广。

关键词: 卡培他滨, 化疗, 双周方案

Abstract: As an oral chemotherapy drug, capecitabine is safe, effective and easy to use, has been widely used in esophageal cancer, gastric cancer, colorectal cancer, breast cancer, ovarian cancer and other solid tumor. The chemotherapy scheme mainly for 3 weeks, each cycle of capecitabine for 14 days, and 7 days off. As a modification to conventional chemotherapy, the biweekly scheme with capecitabine showed low toxicity and well tolerated by patients, short hospitalization time and other characteristics, it is worth of application in clinical.

Key words: capecitabine, chemotherapy, biweekly scheme

中图分类号: